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Abstract
Introduction: Mesenchymal stem cells can potentially be used in therapy for spinal cord injury (SCI).
Methylprednisolone sodium succinate (MPSS) has been used as a scavenging agent in acute SCI treatment, but its
use no longer recommended. This study aimed to identify ways to reduce the usage and risk of high doses of
glucocorticoid steroids, and determine whether AD-MSCs could be used as an early alternative treatment modality
for acute SCI.
Methods: Sixteen adult beagle dogs with SCI were assigned to four treatment groups: control, MPSS, AD-MSCs,
and AD-MSCs + MPSS. Additionally, one dog was used to evaluate the distribution of AD-MSCs in the body after
injection. AD-MSCs (1 × 107 cells) were injected intravenously once a day for 3 days beginning at 6 hours post-SCI.
MPSS was also injected intravenously according to the standard protocol for acute SCI. A revised Tarlov scale was
used to evaluate hindlimb functional recovery. The levels of markers for oxidative metabolism (3-nitrotyrosine,
4-hydroxynonenal, and protein carbonyl) and inflammation (cyclooxygenase-2, interleukin-6, and tumor necrosis
factor-α) were also measured.
Results: At 7 days post-treatment, hindlimb movement had improved in the AD-MSCs and AD-MSCs + MPSS
groups; however, subjects in the groups treated with MPSS exhibited gastrointestinal hemorrhages. Hematoxylin
and eosin staining revealed fewer hemorrhages and lesser microglial infiltration in the AD-MSCs group. The green
fluorescent protein-expressing AD-MSCs were clearly detected in the lung, spleen, and injured spinal cord; however,
these cells were not detected in the liver and un-injured spinal cord. Levels of 3-nitrotyrosine were decreased in the
MPSS and AD-MSCs + MPSS groups; 4-hydroxynenonal and cyclooxygenase-2 levels were decreased in all treatment
groups; and interleukin-6, tumor necrosis factor-α, and phosphorylated-signal transducer and activator transcription
3 levels were decreased in the AD-MSCs and AD-MSCs + MPSS groups.
Conclusion: Our results suggest that early intravenous injection of AD-MSCs after acute SCI may prevent further
damage through enhancement of antioxidative and anti-inflammatory mechanisms, without inducing adverse
effects. Additionally, this treatment could also be used as an alternative intravenous treatment modality for acute SCI.
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Introduction
Spinal cord injury (SCI) results from the primary mechan-
ical damage that occurs when structural thresholds are
surpassed, which in turn leads to immediate physical and
biochemical alterations. These alterations are followed by
a secondary injury mechanism that includes a variety of
vascular, biochemical, and cellular processes [1]. SCI is
generally followed by immediate hematoma formation
and oxidative and inflammatory responses. These events
involve enzyme activation, mediator release, inflammatory
cell migration, glial activation, and neuronal tissue degrad-
ation [2, 3]. Hemorrhages cause the extracellular spaces in
the spinal cord to become exposed to hemoglobin and its
breakdown products, which subsequently results in free
radical generation. Infiltrating neutrophils can directly
damage tissue by producing reactive oxygen species and
secreting proinflammatory mediators [4]. Moreover,
microglial activation is involved in clearing the hematoma,
and activated microglia secrete a variety of cytokines. Fol-
lowing SCI, the progression of these events inhibits axonal
regeneration in the central nervous system, such that pa-
tients are unable to recover from the neurological
damage.
The neuroprotective agent methylprednisolone sodium
succinate (MPSS) has been widely used in the clinical
treatment of acute SCI [5, 6]. However, recent retrospect-
ive cohort studies have demonstrated the lack of a statisti-
cally significant difference between clinical outcomes in
SCI patients treated with and without MPSS [7]. The
therapeutic effect of MPSS on SCI therefore remains con-
troversial. As the current standard effective therapeutic
agent for the clinical treatment of acute SCI, MPSS has
been shown to alleviate secondary injury by decreasing
inflammation and spinal cord ischemia, as well as by inhi-
biting cell membrane lipid peroxidation (LP). However,
administration of high doses of glucocorticoid steroids
causes many complications, including increased incidence
of infection, pneumonia, pressure sores, gastrointestinal
bleeding, and deep vein thrombosis [8].
Much of the current research on SCI is focused on de-
veloping treatment methods that limit or prevent second-
ary injury. Minimizing secondary injury is generally
achieved by ensuring adequate perfusion and oxygenation
and by ancillary administration of neuroprotective agents
for improving clinical signs. Transplantation of mesenchy-
mal stem cells (MSCs) has been shown to provide neuro-
protection, increase neuronal regeneration, and ameliorate
the clinical signs of SCI [9, 10]. In these studies, the trans-
planted MSCs not only improved the inflammatory envir-
onment and enhanced the survival of endogenous nerve
cells, but also reduced fibrosis formation and were able to
partially differentiate into neural cells [9, 11].
We hypothesized that adipose-derived MSCs (AD-
MSCs) intravenously transplanted into animals with acute
SCI would alleviate inflammation at the injured site be-
cause of their antioxidant and anti-inflammatory proper-
ties. Based on our hypothesis, administration of AD-MSCs
should ultimately result in less scar tissue formation, aid
ingrowth of neural progenitor cells, and improve limb
function. The present study was conducted to reduce the
usage and risk of high doses of glucocorticoid steroids,
and to determine whether AD-MSCs could be used as an
early alternative treatment modality for acute SCI.
Methods
Isolation and culture of canine AD-MSCs
MSCs derived from the adipose tissue of canine hip fat
were isolated and characterized [11]. Specifically, adipose
tissue was collected aseptically from the subcutaneous
fat of a 2-year-old beagle dog under anesthesia. Tissues
were washed with phosphate-buffered saline (PBS),
minced, and digested with collagenase type I (1 mg/ml;
Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 30–60
minutes with intermittent shaking. The suspension was
filtered through a 100 μm nylon mesh and centrifuged
to separate floating adipocytes from stromal cells. Prea-
dipocytes in the stromal vascular fraction were plated at
8000–10,000 cells/cm2 in T175 culture flasks containing
Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL,
Grand Island, NY, USA) supplemented with 3.7 g/l so-
dium bicarbonate, 1 % penicillin and streptomycin,
1.7 mML-glutamine, 0.1 mM β-mercaptoethanol, and
10 % fetal bovine serum (FBS). The cells were incubated
in a humidified atmosphere at 37 °C with 5 % CO2. Un-
attached cells and residual nonadherent red blood cells
were removed after 24 hours using a PBS wash, and the
cell medium was replaced every 2 days. At passage 3, the
cells were used for the following experiments.
Animals
Seventeen healthy 2–3-year-old beagle dogs weighing
8.5 ± 2.2 kg were used in the study. All dogs were clinic-
ally judged to be in good health and to have a normal
neurological status. During the experiment, all dogs were
cared for in accordance with the animal care guidelines
of the Institute of Laboratory Animal Resources at Seoul
National University, Korea. Sixteen dogs were assigned
to four groups based on the treatments: control (no
treatment after SCI; n = 4), MPSS (administration of
MPSS after SCI; n = 4), AD-MSCs (administration of
AD-MSCs; n = 4), and AD-MSCs +MPSS (administra-
tion of both AD-MSCs and MPSS; n = 4). One additional
dog was used to evaluate distribution of MSCs in the
body after injection. The Institutional Animal Care and
Use Committee of Seoul National University approved
the experimental design (SNU-111102-8).
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Induction of SCI
SCI was induced using a previously described balloon
compression method [10]. Briefly, the dogs were medi-
cated and anesthetized with tramadol (4 mg/kg intraven-
ously, Toranzin; Samsung Pharm. Ind. Co., Seoul, Korea),
propofol (6 mg/kg intravenously, Provive 1 %; Claris Life-
sciences, Ahmedabad, India), and atropine sulfate
(0.05 mg/kg subcutaneously, Atropine; Jeil Pharm., Yon-
gin, Korea). Anesthesia was maintained with isoflurane
(Forane solution; Choongwae Pharm. Co., Seoul, Korea) at
a minimum alveolar concentration (MAC) of 1.5 through-
out the procedure. Electrocardiography, pulse oximetry,
respiratory gas analysis, and rectal temperature measure-
ment were performed using an anesthetic monitoring sys-
tem (Datex-Ohmeda S/5; GE Healthcare, Little Chalfont,
UK). The dogs were suspended in a ventral recumbent
position, and hemilaminectomy was performed through a
left paramedian approach at the fourth lumbar segment
(L4). A hole of 3–5 mm was made in the left vertebral
arch at L4 using a high-speed pneumatic burr, and a 4-
French embolectomy catheter (Edwards Lifesciences, Ir-
vine, CA, USA) was inserted into the hole. Under fluoro-
scopic guidance, the balloon catheter was advanced until
the tip was positioned at the cranial margin of the first
lumbar segment (L1) vertebral body. The balloon was
then inflated by injecting 50 μl/kg contrast agent (Omni-
paque; GE Healthcare) diluted with saline in a 50:50 pro-
portion. The balloon’s positioning was confirmed using
fluoroscopy. According to a previous study [9], this SCI
model occludes more than 85 % of the spinal canal, as
confirmed by computed tomography. Following induc-
tion of the injury, the soft tissue and skin were closed
using standard methods. The balloon was fixed with a
Chinese finger-type suture and removed after 6 hours.
After the operation, the dogs were monitored in an
ICU, and manual bladder expression was performed at
least three times daily if needed.
Administration of MPSS and AD-MSCs
Administration of MPSS and AD-MSCs was initiated fol-
lowing removal of the embolectomy catheter. MPSS
(30 mg/kg, Methysol; Kunhwa Pharmaceutical Co., Seoul,
Korea) was bolus injected into the cephalic vein and
followed by continuous rate infusion (5.4 mg/kg/hour) for
the next 47 hours [6]. A suspension of 1 × 107 allogenic
AD-MSCs in 10 ml lactated Ringer’s solution was admin-
istered intravenously once a day for 3 successive days.
Labeling and tracking of AD-MSCs
Twenty-four hours before transfection, 4 × 106 HEK293
cells were seeded into a 100 mm dish. The following day,
a lentiviral packaging mix (System Biosciences, San Diego,
CA, USA) encoding viral proteins Gag-Pol, Rev, and VSV-
G and lentiviral transgene plasmids were transfected into
each well for lentivirus production using Turbofect
(Thermo Scientific, Waltham, MA, USA). Green fluores-
cent protein (GFP)-expressing virus particles were col-
lected and transduced into AD-MSCs at passage 1. After
the AD-MSCs reached 90 % confluence, the cells were
selected by puromycin (3 μg/ml; Gibco-BRL). Approxi-
mately 30 % of cells were successfully transduced after
puromycin selection. The AD-MSCs were subcultured,
and passage 3 cells were used for the following experi-
ments. The GFP-labeled AD-MSCs were intravenously
injected after SCI as already described. The dog was sacri-
ficed at 7 days after transplantation and tissue samples
from the lung, liver, spleen, normal spinal cord, and in-
jured spinal cord were collected. GFP protein was identi-
fied in each specimen using western blot analysis. The
injured spinal cord was fixed in a 10 % formalin solution
and embedded in paraffin. Longitudinal sections were
made and the tissue was stained with 4′,6-diamidino-2-
phenylindole (DAPI, 1:100; Sigma-Aldrich) to identify nu-
clei. Slides were observed using a fluorescent microscope.
Clinical assessment
Behavioral assessments were performed on days 2, 4,
and 7 after the operation to evaluate functional recovery
of the hind limbs. Each dog was videotaped from both
sides and behind during the neurologic examination.
Using video footage and the revised Tarlov scale [12],
the dogs’ gaits were scored independently by two indi-
viduals blinded to the experimental condition. The ani-
mal’s vital signs and operation site were also checked. A
fecal occult blood test (Cell Biolabs, Inc., San Diego, CA,
USA) was performed to evaluate any adverse gastro-
intestinal effects of intravenous administration of AD-
MSCs and/or MPSS.
Histopathological assessment
The dogs were sacrificed through intravenous injection
of potassium chloride under general anesthesia at 7 days
after transplantation. The spinal cord from the 12th
thoracic segment (T12) to the third lumbar segment
(L3) was extracted by dissection. Each section was then
placed in 10 % sucrose/PBS at 4 °C for 12 hours and
subsequently immersed in 20 % sucrose solution over-
night at 4 °C. The sample was divided into two parts
longitudinally. One-half of each section was immediately
frozen with liquid nitrogen for western blot analysis and
enzyme-linked immunosorbent assay (ELISA) tests. The
other half was embedded in optimal cutting temperature
compound (Surgipath®; Leica Biosystems Richmond,
Inc., Richmond, IL, USA), frozen, and cut longitudinally
into 12 μm sections with a cryomicrotome. These sections
were mounted on silane-coated glass slides and stained
with hematoxylin and eosin (H&E) or Luxol fast blue
stain. The hemorrhagic area was measured by tracing the
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hemorrhagic margin and calculated using an image analysis
program (ImageJ; NIH, Bethesda, MD, USA). The number
of microglia was counted manually in the high-powered field
from five randomly selected areas of the injured area margin.
Oxidant metabolite assessment
The peroxynitrite (PN) formation of 3-nitrotyrosine (3-
NT), the LP product 4-hydroxynenonal (4-HNE), and
the protein oxidation-derived protein carbonyls (PC)
were used as markers for oxidative damage. The level
of each oxidation product (3-NT, 4-HNE, and PC) was
assessed using ELISA kits (Cell Biolabs, Inc.). The sam-
ples were placed into the wells of the 3-NT, 4-HNE,
and PC conjugate-coated plates and incubated at room
temperature for 10 minutes. After incubation, the second-
ary antibody was added to each of the wells, incubated at
room temperature for 1 hour, washed three times with
washing buffer, and incubated with secondary antibody–
horseradish peroxidase conjugate for 1 hour. The wells
were washed, the substrate solution added for color
change, and absorbance measured at 450 nm.
Western blot analysis
The organ tissues and the frozen half of each injured
spinal cord specimen were used for western blot analysis.
Briefly, the tissue was washed twice with PBS, and then
homogenized with a sonicator in lysis buffer (20 mM Tris
at pH 7.5, 1 mM ethylenediaminetetraacetic acid, 1 mM
ethylene glycol tetraacetic acid, 1 % Triton X-100, 1 mg/
ml aprotinin, 1 mM phenylmethylsulfonylfluoride,
0.5 mM sodium orthovanadate) on ice for 30 minutes.
Lysates were cleared by centrifugation (10 minutes at
15,000 rpm, 4 °C), and protein concentrations were deter-
mined using the Bradford method [13]. Equal amounts of
protein (20 μg) were resolved by electrophoresis on 10 %
sodium dodecyl sulfate–polyacrylamide gels and trans-
ferred to polyvinylidene fluoride membranes. Membrane
blots were washed with TBST (10 mM Tris–HCl, pH 7.6,
150 mM NaCl, 0.05 % Tween-20), blocked with 5 %
skimmed milk for 1 hour, and incubated with the appro-
priate primary antibodies at the recommended dilutions.
The antibodies used included antibodies against actin
(A3853; Sigma-Aldrich), GFP (MA515256; Thermo Scien-
tific), interleukin (IL)-6 (ab6672; Abcam, Cambridge, UK),
and cyclooxygenase-2 (COX-2, sc-7951), tumor necrosis
factor alpha (TNFα, sc-1350), phosphorylated signal trans-
ducer and activator of transcription 3 (pSTAT3, sc-8001-
R), β3-tubulin (sc-69966), glial fibrillary acidic protein
(GFAP, sc-65343), and galactosylceramidase (GalC, sc-
67352) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The primary antibodies (1:1000) were diluted in TBST.
The membrane was then washed, and the primary anti-
bodies were detected with goat anti-rabbit IgG or goat
anti-mouse IgG conjugated to horseradish peroxidase
(1:5000; Invitrogen, Waltham, MA, USA). Bands were vi-
sualized using enhanced chemiluminescence (Invitrogen).
Statistical analysis
All results are expressed as mean ± standard deviation
(SD). Statistical analysis was performed using a com-
mercially available statistical software program (SPSS
Statistics, version 21.0; IBM Corp., Armonk, NY, USA).
In all experiments, Kruskal–Wallis tests were followed
by Mann–Whitney U tests to compare between groups.
P <0.05 was considered significant.
Results
Clinical assessment
All experimental dogs had no movement and muscle tone
in the hind limbs after SCI. However, subjects in the AD-
MSCs group had significantly enhanced motor function
compared with those in the control group at 7 days post
treatment (P <0.05; Fig. 1, Table 1). In addition, gastro-
intestinal hemorrhage was not observed in the control
and the AD-MSCs groups but was observed in the MPSS
and AD-MSCs +MPSS groups until 4 days post SCI
(Table 2). Additionally, one in four dogs in the AD-MSCs
+MPSS group and one in three dogs in the MPSS group
exhibited gastrointestinal hemorrhages at 4 days post SCI.
Other adverse effects such as wound infections or delayed
healing were not observed in any of the treatment groups.
Distribution of AD-MSCs
To determine the engraftment of intravenously injected
AD-MSCs, GFP was examined at 7 days after adminis-
tration of GFP-expressing AD-MSCs. GFP was detected
in the lung, spleen, and injured spinal cord, but was not
detected in the liver and uninjured spinal cord (Fig. 2a).
The expression of GFP in the lung was relatively higher
Fig. 1 Revised Tarlov scores. Motor function outcome at 7 days
after MPSS and AD-MSCs administration. The AD-MSCs group had
significantly enhanced motor function compared with the control
group at 7 days post treatment. × mean. *P <0.05 compared with
the control group. AD-MSCs adipose-derived mesenchymal stem
cells, MPSS methylprednisolone sodium succinate
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than other organ tissues. GFP-labeled AD-MSCs were
observed in the epicenter of the injured spinal cord
(Fig. 2b).
Histopathological assessment
Seven days after the initial transplantation, the average
damaged lesion size per section of groups was 68.4 ±
4.5 mm2. There were no significant differences in the
area of the lesion among the four groups (Fig. 3). In the
low-powered field, H&E-stained sections from all
groups showed severe hemorrhage and infiltration of
microglial cells in the injured part of the spinal cord. In
the high-powered field, an injured spinal cord paren-
chyma composed of demyelinated neurons, cell debris,
and mild fibrosis as well as hemorrhage was observed.
Luxol fast blue staining also showed demyelination in
the injured area. However, hemorrhages were less com-
monly observed in the AD-MSCs group and a lower in-
flammatory response was observed in the AD-MSCs
and AD-MSCs +MPSS groups (Fig. 4).
Antioxidant effects
The level of 3-NT (a PN marker) was significantly de-
creased in the MPSS and AD-MSCs +MPSS groups
compared with other groups (P <0.05; Fig. 5). The level
of 4-HNE (an LP product) was significantly decreased
in all treatment groups compared with the control
group (P <0.05). In addition, the level of PC (a protein
oxidation-related product) was significantly decreased
in the AD-MSCs and AD-MSCs +MPSS groups com-
pared with the other two groups (P <0.05).
Anti-inflammatory effects
A decrease in the level of COX-2 was observed in the
MPSS group (P <0.05); however, IL-6 and TNFα levels
were not significantly different from that of the control
group (Fig. 6a). On the other hand, the levels of COX-2,
IL-6, and TNFα were significantly decreased in the AD-
MSCs and AD-MSCs +MPSS groups when compared
with those in the control group (P <0.05).
Astrogliosis and neuronal cells
The expression of pSTAT3 was significantly decreased in
the AD-MSCs and AD-MSCs +MPSS groups when
Table 1 Revised Tarlov scores
Group n Mean Standard deviation P value
Control 4 1.00 0 0.317
MPSS 4 1.50 1.00
Control 4 1.00 0 0.046
AD-MSCs 4 2.00 0.82
Control 4 1.00 0 0.131
AD-MSCs +MPSS 4 1.75 0.96
MPSS 4 1.50 1.00 0.350
AD-MSCs 4 2.00 0.82
MPSS 4 1.50 1.00 0.617
AD-MSCs +MPSS 4 1.75 0.96
AD-MSCs 4 2.00 0.82 0.647
AD-MSCs +MPSS 4 1.75 0.96
P values were calculated using the Mann–Whitney U test
AD-MSCs adipose-derived mesenchymal stem cells, MPSS methylprednisolone
sodium succinate
Table 2 Percentage of gastrointestinal hemorrhage
Group Time after treatment
2 days 4 days 7 days
Control 0 % (0/4) 0 % (0/4) 0 % (0/4)
MPSS 100 % (4/4) 75 % (3/4) 0 % (0/4)
AD-MSCs 0 % (0/4) 0 % (0/4) 0 % (0/4)
AD-MSCs +MPSS 100 % (4/4) 25 % (1/4) 0 % (0/4)
AD-MSCs adipose-derived mesenchymal stem cells, MPSS methylprednisolone
sodium succinate
Fig. 2 GFP distribution at 7 days after treatment. a GFP was detected
in the lung, spleen, and injured spinal cord at 7 days after intravenous
administration of AD-MSCs. However, GFP was not detected in the liver
and uninjured normal spinal cord. b GFP-labeled AD-MSCs were
observed in the epicenter of the injured spinal cord. Bar: 50 μm. DAPI
4′,6-diamidino-2-phenylindole, GFP green fluorescent protein
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compared with the control group (P <0.05; Fig. 6b). In
addition, β3-tubulin levels were increased in all treatment
groups as compared with the control group (P <0.05). The
levels of GFAP, a marker of reactive astrocytes, and GalC,
a marker of mature oligodendrocytes, were increased in
the AD-MSCs and AD-MSCs +MPSS groups when com-
pared with those in the control group.
Discussion
The objective of this study was to investigate the antioxi-
dant and anti-inflammatory effects of intravenously
injected AD-MSCs in an acute SCI model and to com-
pare these effects with those of MPSS, which is used as
a neuroprotective agent for the treatment of acute SCI.
Administration of AD-MSCs improved hind-limb func-
tions and reduced the occurrence of adverse effects that
are associated with high doses of glucocorticoid steroids.
MPSS treatment also resulted in some beneficial effects
on the clinical signs, but resulted in the adverse effect of
gastrointestinal hemorrhage caused by peptic ulceration.
This complication may develop because MPSS inhibits
phospholipase A2 action, which converts arachidonic
acid to COX. These actions of MPSS lead to nonselective
inhibition of COX-1 and COX-2. The COX-2 enzyme is
involved in inflammatory responses, especially prostaglan-
din E2, but COX-1 is thought to only be involved in
normal physiological functions, such as gastrointestinal
mucous production, kidney water excretion, and platelet
activation [14]. However, AD-MSCs administration did not
produce this adverse effect, which suggests that MSCs se-
lectively inhibit COX-2, but not COX-1. It is therefore im-
portant to minimize gastrointestinal effects, since they can
Fig. 3 Histologic analysis of spinal cord lesions stained with H&E and Luxol fast blue. Control group a–c, MPSS group d–f, AD-MSCs group g–i,
and AD-MSCs + MPSS group j–l were observed. In the H&E staining a, d, g, j, all groups showed severe hemorrhage and infiltration of microglial
cells in the injured part of the spinal cord. The injured parenchyma of spinal cord was composed of demyelinated neurons, cell debris, mild fibrosis,
and hemorrhage in the high-powered field b, e, h, k. The AD-MSCs group showed less hemorrhaging and fewer inflammatory responses compared
with other groups. In addition, all groups exhibited severe demyelination of nerve fibers in the SCI lesion stained with Luxol fast blue c, f, i, l. Bar: a, d,
g, j 200 μm; b, c, e, f, h, i, k, l 25 μm
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result in fatal conditions such as gastrointestinal perfor-
ation, anemia, secondary infection, and sepsis if left un-
treated [15, 16].
In the present study, administration of MPSS inhib-
ited nitration and LP, and AD-MSCs inhibited LP and
protein oxidation. These antioxidant effects of MPSS
correspond well with those reported previously [17].
The effects of MPSS were due to a membrane stabiliz-
ing action that inhibits LP by limiting the fluidity of the
phospholipids in the neural cell membranes, thereby
stunting the LP chain reaction. The MSCs exhibited
antioxidant activity through LP prevention, increasing
levels of glutathione and superoxide dismutase, and
modulating the pathways of antioxidant-related protein
activation [18]. Moreover, the histopathological findings in
the present study showed that AD-MSCs transplantation
reduced intraparenchymal hemorrhage, reduced migration
of microglia, and decreased the expression of oxidative
metabolites. The reduced hemorrhaging caused by AD-
MSCs administration might directly reduce the release of
free radicals from hematomas in addition to reducing
microglial activation. In this study, AD-MSCs and MPSS
both showed antioxidant effects, but appeared to do so by
different mechanisms. Accordingly, a combination therapy
of AD-MSCs and MPSS for acute SCI was required for
optimal antioxidation with fewer adverse effects.
Fig. 4 a The hemorrhagic area was decreased in the AD-MSCs group compared with other groups. b The infiltration of microglia was decreased in the
AD-MSCs and AD-MSCs +MPSS groups. Data presented as mean ± SD. *P <0.05 compared with the control group. AD-MSCs adipose-derived mesenchy-
mal stem cells, HPF high-powered field, MPSS methylprednisolone sodium succinate
Fig. 5 Oxidant metabolite levels (3-NT, 4-HNE, and PC) at 7 days after treatment. The level of 3-NT was decreased in the MPSS and AD-MSCs +MPSS
groups compared with the other groups. The level of 4-HNE was decreased in all treatment groups compared with the control group. In addition, the
level of PC was decreased in the AD-MSCs and AD-MSCs + MPSS groups when compared with the other two groups. Data presented as mean
± SD. *P <0.05 compared to the control group. AD-MSCs adipose-derived mesenchymal stem cells , 4-HNE 4-hydroxynenonal, MPSS methylpredniso-
lone sodium succinate, 3-NT 3-nitrotyrosine, PC protein carbonyls
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In the present study, intravenous injection of AD-MSCs
decreased levels of inflammatory cytokines including
COX-2, IL-6, and TNFα, which may have resulted from
the inhibition of microglial activation and inflammatory
responses. However, MPSS does not decrease levels of IL-
6 and TNFα, and it seems that high doses of MPSS exert
greater antioxidant effect than anti-inflammatory effects
[19]. In addition, the unclear neurological improvement
and anti-inflammatory effects of MPSS in the present
study might support the results indicating a low thera-
peutic effect. Previous studies have reported that MSCs
exert immunomodulatory effects by attenuating and
modulating excessive inflammatory reactions [20, 21].
MSCs have been shown to reduce levels of proinflamma-
tory cytokines such as interferon gamma, TNFα, and IL-6
and to increase expression of indoleamine 2,3-dioxygen-
ase, which suppresses T-cell responses and promotes im-
munological tolerance [22]. In spinal microglia, IL-6 is
associated with inflammatory cytokine signaling to in-
duce STAT3, and also has the ability to trigger reactive
astrogliosis [23, 24]. In the present study, AD-MSCs de-
creased levels of IL-6 which is related to pSTAT3 and
astrogliosis, suggesting an anti-astrogliosis effect. React-
ive astrocytes contribute to glial scar formation and inhib-
ition of axonal outgrowth. According to recent studies,
however, reactive astrocytes also provide beneficial effects
that protect adjacent neural tissue and secrete growth-
promoting neurotrophic factors [25, 26]. The existing
GFAP-expressing reactive astrocytes could create the
neuroprotective environment for neurogenesis with trans-
planted cells.
MSCs transplantation strategies require a safe and effi-
cient method of cellular delivery. In animal models of SCI,
the most common delivery method is direct injection into
the injured site, which allows many cells to be trans-
planted effectively, albeit through an extremely invasive
procedure that may lead to further injuries. Consequently,
this method may be very difficult to implement in human
subjects. Therefore, less invasive methods for cell delivery
have been investigated and intravenous administration has
been identified as an ideal and preferable minimally inva-
sive method for delivering cell transplants for clinical
translation. Nonetheless, the actions and cellular distribu-
tion of intravenously transplanted cells is a subject of con-
troversy. Previous study showed that transplanted cells
even survived for at least several weeks following intraven-
ous transplantation of MSCs in animal models of SCI
[27]. However, other studies reported that intravenously
transplanted cells were primarily trapped in the lung, and
secondarily in the spleen, liver, and kidney, with only a
precious few cells found at the injured site [20, 28]. In the
present study, we detected grafted cells in the lung, spleen,
Fig. 6 Inflammation and astrogliosis at 7 days after treatment. a Inflammatory markers (COX-2, IL-6, TNF-α). COX-2 levels were decreased in all
treatment groups. The levels of IL-6 and TNFα were decreased in AD-MSCs and AD-MSCs +MPSS groups. b Astrogliosis and neuronal markers (pSTAT3,
β3-tubulin, GFAP, GalC). Expression of pSTAT3 was decreased in the AD-MSCs and AD-MSCs +MPSS groups. β3-tubulin levels were increased in all
treatment groups. Data presented as mean ± SD. *P <0.05 compared with the control group. AD-MSCs adipose-derived mesenchymal stem cells, COX
cyclooxygenase, GalC galactosylceramidase, GFAP glial fibrillary acidic protein, IL interleukin, MPSS methylprednisolone sodium succinate, pSTAT3 phos-
phorylated signal transducer and activator of transcription 3, TNFα tumor necrosis factor alpha
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and injured spinal cord site, but found no such cells in the
uninjured spinal cord after intravenous administration,
which shows that the AD-MSCs can probably migrate into
the injured spinal cord through the broken blood–spinal
cord barrier.
The MSCs therapy was a result of indirect environ-
mental modification rather than direct translineage con-
version of migrated MSCs to functional
oligodendrocytes or neurons [11]. Transplanted MSCs
were able to reduce neurotoxicity and protect cells from
apoptosis. MSCs secrete anti-apoptotic protein B-cell
lymphoma 2 (Bcl-2), and prevent the release of Bcl-2-
associated X protein and caspase 3, which are proapopto-
tic proteins [29, 30]. MSCs also act as neuroprotectors by
secreting various angiogenic and neurotrophic factors
such as brain-derived neurotrophic factor, nerve growth
factor, vascular endothelial growth factor, and hepatocyte
growth factor, thereby providing trophic support to dam-
aged neurons [31]. In the present study, intravenous injec-
tion of AD-MSCs and/or MPSS increased levels of
neuronal markers including β3-tubulin and GalC. This
could be the result of endogenous neuronal cells that sur-
vived in the injured site through the protective effects of
AD-MSCs. Furthermore, intravenously injected MSCs
show peripheral immunoregulatory properties through in-
hibition of T-cell activities and through modulation of the
host systemic and central nervous system inflammatory
responses [32, 33]. It has been suggested that intraven-
ously injected MSCs may not only be involved in systemic
immune modulation, but may also migrate to the injured
site to exert neuroprotective effects.
Conclusion
In the current study, it is clear that the spinal cord under-
went primary and secondary damages resulting from SCI.
In this hostile environment, it is difficult to maintain
cell survival, differentiation, and neuronal regeneration.
Therefore, it is important to improve the environment
by decreasing oxidative damage, LP, and inflammatory
responses in order to protect intrinsic neural cells and
recover their function. The MPSS treatment in SCI is
controversial since it provides only modest neurological
benefit despite the risk of serious adverse effects. Our
results demonstrated that the intravenous injection of
AD-MSCs in the acute spinal cord injured dog pro-
duced beneficial effects through enhancement of anti-
oxidant and anti-inflammatory activities, and could be
used as an alternative treatment modality in acute SCI.
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